Pembrolizumab for Early Triple-Negative Breast CancerPeter Schmid, Joyce O’Shaughnessy, Gursel Aktan et al.|New England Journal of Medicine|2020Cited by 3.1k
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trialJavier Cortés, Gallardo Carlos, David W. Cescon et al.|The Lancet|2020Cited by 1.8k
Inavolisib-Based Therapy in <i>PIK3CA</i> -Mutated Advanced Breast CancerNicholas C. Turner, Komal Jhaveri, Seock‐Ah Im et al.|New England Journal of Medicine|2024Cited by 235
Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor–Positive Breast CancerPeter Schmid, Alastair M. Thompson|Journal of Clinical Oncology|2016Cited by 96
Overall Survival with Inavolisib in <i>PIK3CA</i> -Mutated Advanced Breast CancerKomal Jhaveri, Nicholas C. Turner, Seock‐Ah Im et al.|New England Journal of Medicine|2025Cited by 79